ONCY vs OSTX

Oncolytics Biotech Inc. vs OS Therapies Incorporated — Valuation Comparison 2026

ONCY

Biotechnology
Oncolytics Biotech Inc.
Quality
3.4
out of 10
Value Trap
Price
$0.94
Last close
Models
7/13
Active
VS

OSTX

Biotechnology
OS Therapies Incorporated
Quality
3.1
out of 10
Value Trap
12
SAFE
Price
$1.98
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType ONCY Fair ValueONCY Upside OSTX Fair ValueOSTX Upside
Bayesian DCF Intrinsic $0.27 -70.9% $0.52 -74.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.16 -82.7% $0.04 -98.1%
PWERM Option-Based $0.99 +6.2% $2.10 +5.9%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ONCY vs OSTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ONCY vs OSTX — Which Stock Is More Undervalued?

ONCY scores higher with a 3.4/10 quality rating vs OSTX's 3.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Oncolytics Biotech Inc. (ONCY) and OS Therapies Incorporated (OSTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ONCY currently trades at $0.94 with a QOC of 3.4/10, while OSTX trades at $1.98 with a QOC of 3.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).